Burke J - Search Results

1

Bimatoprost sustained-release intracameral implant reduces episcleral venous pressure in dogs.

Lee SS, Burke J, Shen J, Almazan A, Orilla W, Hughes P, Zhang J, Li H, Struble C, Miller PE, Robinson MR. Lee SS, et al. Among authors: burke j. Vet Ophthalmol. 2018 Jul;21(4):376-381. doi: 10.1111/vop.12522. Epub 2018 Feb 19. Vet Ophthalmol. 2018. PMID: 29457333 Clinical Trial.

2

Topical application of 0.005% latanoprost increases episcleral venous pressure in normal dogs.

Tsai S, Miller PE, Struble C, Howard S, Almazan A, Burke JA, Hughes PM, Li H, Conforti P, Lee SS, Robinson MR. Tsai S, et al. Vet Ophthalmol. 2012 Mar;15 Suppl 1:71-8. doi: 10.1111/j.1463-5224.2011.00970.x. Epub 2011 Nov 30. Vet Ophthalmol. 2012. PMID: 22129101 Clinical Trial.

3

Iridocorneal angle measurements in mammalian species: normative data by optical coherence tomography.

Almazan A, Tsai S, Miller PE, Lee SS, Vilupuru AS, Burke JA, Robinson MR. Almazan A, et al. Vet Ophthalmol. 2013 Mar;16(2):163-6. doi: 10.1111/j.1463-5224.2012.01030.x. Epub 2012 May 22. Vet Ophthalmol. 2013. PMID: 22612298

4

Intraocular Pressure Effects and Mechanism of Action of Topical Versus Sustained-Release Bimatoprost.

Lee SS, Almazan A, Decker S, Zhong Y, Ghebremeskel AN, Hughes P, Robinson MR, Burke JA, Weinreb RN. Lee SS, et al. Transl Vis Sci Technol. 2019 Jan 30;8(1):15. doi: 10.1167/tvst.8.1.15. eCollection 2019 Jan. Transl Vis Sci Technol. 2019. PMID: 30713809 Free PMC article.

5

Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.

Seal JR, Robinson MR, Burke J, Bejanian M, Coote M, Attar M. Seal JR, et al. Among authors: burke j. J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):50-57. doi: 10.1089/jop.2018.0067. Epub 2018 Oct 18. J Ocul Pharmacol Ther. 2019. PMID: 30335560 Free PMC article.

6

The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs.

Tsai S, Almazan A, Lee SS, Li H, Conforti P, Burke J, Miller PE, Robinson MR. Tsai S, et al. Among authors: burke j. Vet Ophthalmol. 2013 Sep;16(5):370-6. doi: 10.1111/vop.12011. Epub 2012 Dec 10. Vet Ophthalmol. 2013. PMID: 23227993 Clinical Trial.

7

Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant.

Ghosn CR, Li Y, Orilla WC, Lin T, Wheeler L, Burke JA, Robinson MR, Whitcup SM. Ghosn CR, et al. Invest Ophthalmol Vis Sci. 2011 May 2;52(6):2917-23. doi: 10.1167/iovs.10-5939. Invest Ophthalmol Vis Sci. 2011. PMID: 21273539

8

Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.

Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF. Chang-Lin JE, et al. Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4605-9. doi: 10.1167/iovs.10-6387. Invest Ophthalmol Vis Sci. 2011. PMID: 21421864

9

Ocular changes after photodynamic therapy.

Tzekov R, Lin T, Zhang KM, Jackson B, Oyejide A, Orilla W, Kulkarni AD, Kuppermann BD, Wheeler L, Burke J. Tzekov R, et al. Among authors: burke j. Invest Ophthalmol Vis Sci. 2006 Jan;47(1):377-85. doi: 10.1167/iovs.05-0838. Invest Ophthalmol Vis Sci. 2006. PMID: 16384988

10

Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.

Shen J, Durairaj C, Lin T, Liu Y, Burke J. Shen J, et al. Among authors: burke j. Invest Ophthalmol Vis Sci. 2014 Feb 20;55(2):1056-66. doi: 10.1167/iovs.13-13650. Invest Ophthalmol Vis Sci. 2014. PMID: 24448267

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,212 results

Search Page

Filters